Prelude Therapeutics saw the highest growth of 4.99% in patent filings and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 4.99% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Prelude Therapeutics‘s patent filings and grants. Buy the databook here.
Prelude Therapeutics has been focused on protecting inventions in World Intellectual Property Organization(WIPO) with six publications in Q2 2024
The World Intellectual Property Organization(WIPO) Patent Office dominates the patent filings with nearly 46% of filings. The World Intellectual Property Organization(WIPO), United States(US), Israel(IL), and Australia(AU) patent Office are among the top ten patent offices where Prelude Therapeutics is filings its patents..
Roche and Johnson & Johnson could be the strongest competitors for Prelude Therapeutics
Patents related to rare diseases lead Prelude Therapeutics's portfolio
Prelude Therapeutics has the highest number of patents in rare diseases. For rare diseases, nearly 100% of patents were filed and no patents were granted in Q2 2024.
Breast cancer related patents lead Prelude Therapeutics portfolio followed by ovarian cancer, and pancreatic cancer
Prelude Therapeutics has highest number of patents in breast cancer followed by ovarian cancer, pancreatic cancer, prostate cancer, and bladder carcinoma.
For comprehensive analysis of Prelude Therapeutics's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.